-
Clinical Trial
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
- P Hau, D Koch, T Hundsberger, E Marg, B Bauer, R Rudolph, M Rauch, A Brenner, P Rieckmann, J Schuth, T Jauch, H Koch, and U Bogdahn.
- Department of Neurology, District Medical Center, University of Regensburg, Regensburg, Germany. peter.hau@medbo.de
- Neurology. 2007 Feb 27; 68 (9): 688-90.
AbstractWe surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..